ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.828,52
-0,25%
S&P 500
5.308,15
1,17%
Dow Jones
39.908,00
0,00%
Euro vs US Dollar
1,08654
-0,22%
Bitcoin
66.219,68
-0,06%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. argenx SE (ARGX)

  7. argenx SE (ARGX) News

ARGX argenx SE

376,96
0,00 (0,00%)
Vor Marktöffnung
Zuletzt aktualisiert: 13:32:38
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
argenx SE ARGX NASDAQ Depository Receipt
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
0,00 0,00% 376,96 13:32:38
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
376,96
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
09.5.202413:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09.5.202407:00GLOBEargenx Reports First Quarter 2024 Financial Results and..
08.5.202412:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07.5.202423:30GLOBEargenx announces results of Annual General Meeting of..
07.5.202407:00GLOBEargenx to Present at BofA Securities 2024 Health Care..
02.5.202407:00GLOBEargenx to Report First Quarter 2024 Financial Results and..
16.4.202407:00GLOBEargenx Data Highlight Evidence that VYVGART and VYVGART..
27.3.202407:00GLOBEargenx Advances Clinical Development of Efgartigimod in..
26.3.202421:00GLOBEargenx Announces Annual General Meeting of Shareholders on..
26.3.202407:00GLOBEargenx Announces Approval of VYVGART (efgartigimod alfa) in..
08.3.202412:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07.3.202422:01GLOBEargenx Delivers on Promise to Transform Patient Expectations..
29.2.202422:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29.2.202407:00GLOBEargenx Reports Full Year 2023 Financial Results and Provides..
26.2.202407:00GLOBEargenx to Present at Upcoming Investor Conferences
22.2.202407:00GLOBEargenx to Report Full Year 2023 Financial Results and Fourth..
20.2.202412:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20.2.202407:00GLOBEargenx Announces FDA Acceptance of Supplemental Biologics..
18.1.202412:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18.1.202407:00GLOBEargenx Announces Approval of VYVDURA® (efgartigimod alfa and..
08.1.202412:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08.1.202407:00GLOBEargenx Highlights 2024 Strategic Priorities
02.1.202407:00GLOBEargenx to Present at 42nd Annual J.P. Morgan Healthcare..
20.12.202318:37DJNArgenx Down Nearly 26%, on Pace for Record Percent Decrease..
20.12.202312:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20.12.202307:00GLOBEargenx Reports Topline Results from ADDRESS Study of..
28.11.202317:16DJNArgenx Down Over 10%, On Track for Largest Percent Decrease..
28.11.202313:03DJNArgenx Shares Down After Vyvgart Study Misses Primary..
28.11.202312:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28.11.202307:00GLOBEargenx Reports Topline Results from ADVANCE-SC Study of..
17.11.202312:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16.11.202313:40GLOBEargenx Announces European Commission Approval of..
01.11.202321:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01.11.202307:00GLOBEargenx to Present at Upcoming Investor Conferences
31.10.202314:14EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31.10.202307:00GLOBEargenx Reports Third Quarter 2023 Financial Results and..
24.10.202307:00GLOBEargenx to Report Third Quarter 2023 Financial Results and..
27.9.202322:42EDGAR2Form S-8 - Securities to be offered to employees in employee..
21.9.202314:38EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21.9.202307:00GLOBEargenx Announces VYVGART (efgartigimod alfa) Authorized for..
15.9.202307:00GLOBEargenx Announces Positive CHMP Opinion for Subcutaneous..
30.8.202307:00GLOBEargenx to Present at Upcoming Investor Conferences
27.7.202312:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27.7.202307:00GLOBEargenx Reports Half Year 2023 Financial Results and Provides..
24.7.202322:30GLOBEargenx announces closing of global offering
20.7.202322:51EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
20.7.202307:00GLOBEargenx to Report Half Year 2023 Financial Results and Second..
19.7.202323:58GLOBEargenx announces full exercise of underwriters’ option to..
19.7.202303:30GLOBEargenx raises $1.1 billion in gross proceeds in a global..
17.7.202322:58DJNArgenx Launches $750 Million Global Offering

Kürzlich von Ihnen besucht

NASDAQ
ARGX
argenx
LSE
AAR
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten